Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Expands By 135.3%

OnKure Therapeutics, Inc. (NASDAQ:OKUR) was the target of a significant growth in short interest in February. As of February 13th, there was short interest totaling 33,385 shares, a growth of 135.3% from the January 29th total of 14,187 shares. Based on an average trading volume of 101,537 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.3% of the shares of the stock are short sold. Currently, 0.3% of the shares of the stock are short sold. Based on an average trading volume of 101,537 shares, the days-to-cover ratio is currently 0.3 days.

OnKure Therapeutics Stock Up 1.9%

Shares of NASDAQ OKUR opened at $2.71 on Friday. The stock has a market capitalization of $36.72 million, a PE ratio of -0.57 and a beta of 0.46. The firm has a fifty day moving average of $2.75 and a 200-day moving average of $2.83. OnKure Therapeutics has a 52-week low of $1.70 and a 52-week high of $5.60.

Institutional Investors Weigh In On OnKure Therapeutics

Large investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new stake in shares of OnKure Therapeutics in the second quarter valued at about $25,000. Bailard Inc. bought a new stake in OnKure Therapeutics in the second quarter valued at about $34,000. Jane Street Group LLC acquired a new stake in shares of OnKure Therapeutics during the 4th quarter valued at approximately $56,000. Rangeley Capital LLC acquired a new stake in shares of OnKure Therapeutics during the second quarter worth $71,000. Finally, Barclays PLC raised its stake in OnKure Therapeutics by 4,286.8% during the fourth quarter. Barclays PLC now owns 27,242 shares of the company’s stock worth $79,000 after acquiring an additional 26,621 shares during the period. Institutional investors and hedge funds own 90.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on OKUR shares. Weiss Ratings restated a “sell (d-)” rating on shares of OnKure Therapeutics in a report on Monday, December 22nd. Wall Street Zen raised shares of OnKure Therapeutics to a “sell” rating in a research note on Saturday, November 1st. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $32.00.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.